medigraphic.com

2005, Número 4

<< Anterior Siguiente >>

Med Sur 2005; 12 (4)


El “método mexicano” para hacer trasplantes de células totipotenciales hematopoyéticas alogénicas

Ruiz-Argüelles GJ, Suárez-González L, Gómez-Almaguer D, Ruiz-Delgado GJ

Idioma: Español
Referencias bibliográficas: 58
Paginas: 503-211
Archivo PDF: 86.46 Kb.


RESUMEN

Durante mucho tiempo se consideró, equivocadamente, que la razón por la que los trasplantes de médula ósea eran capaces de curar a los pacientes con hemopatías malignas era porque permitían la administración de cantidades elevadas de quimioterapia y/o radioterapia y que la función de las células trasplantadas era únicamente la de restablecer la hematopoyesis del paciente después de recibir la terapia mieloablativa. Ahora es claro que la razón principal por la que los trasplantes de células hematopoyéticas alogénicas pueden curar a pacientes con neoplasias es por la inducción del efecto de injerto contra tumor, que es parte del efecto de injerto contra huésped. En el año de 1999 se diseñó en México un método para llevar a cabo trasplantes hematopoyéticos que se conoce ahora como el “método mexicano” de acondicionamiento no mieloablativo que supone el uso de fármacos accesibles y baratos como son la ciclofosfamida, el busulfán y la fludarabina. Con este método se han llevado a cabo trasplantes hematopoyéticos en más de 300 pacientes. Aproximadamente una cuarta parte de los pacientes no necesitaron transfusiones de glóbulos rojos y además un tercio no necesitó transfusión de plaquetas. En más del 80% de los casos, el procedimiento del trasplante se pudo completar de manera totalmente extrahospitalaria. La mediana de supervivencia (SV) postrasplante no ha sido alcanzada, y la SV a 2,000 días es de 54%. La mortalidad a 100 días es de 16% y la mortalidad relacionada a trasplante 20%. Los mejores resultados se obtuvieron en LGC en primera fase crónica (92% de supervivencia a 750 días) y los menos halagüeños en leucemia aguda linfoblástica (22% SV a 1,600 días), con cifras intermedias para leucemia aguda mieloblástica (66% SV a 860 días) y anemia aplástica (91% SV a 1,500 días). El costo promedio de cada trasplante es de 18 mil dólares americanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alarcón-Segovia D, Ruiz-Argüelles A, Llorente L. Broken dogma: Penetration of autoantibodies into living cells. Immunol Today 1996; 17:163-164.

  2. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995; 272: 38-47.

  3. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB. Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man? Lancet 1978; 2(8089): 537-40.

  4. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.

  5. Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES (editors). Landmark papers of the twentieth century. Academic Press. San Diego, USA 2000: 741-747.

  6. Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chromic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.

  7. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-62.

  8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.

  9. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.

  10. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividelli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756-763.

  11. Quesenberry PJ, Stewart FM, Becker P, Emmons R, Hsieh C, Werme K, Habibian H, Reilly J, McAuliffe C, Dooner M, Carlson J, Miller C, Lambert JF, Colvin GA, Pang L, Benoit BO, Zhong S, Wang H, Damon J. Stem cell transplantation without myeloablation in immunocompetent recipients. In: Giralt S, Slavin S (editors): Non myeloablative stem cell transplantation. Darwin Scientific Publishing. Abingdon, Oxfordshire, UK. 2000: 11-16.

  12. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O´Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.

  13. Champlin R. Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. In: Schechter GP, Hoffman R, Cthrier SL. Hematology 1999. The American Society of Hematology Education Program Book. Washington, USA. 1999: 413-416.

  14. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Cauncey T, Wolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederweiser D, Storb R. Non-myeloablative hematopoietic stem cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci 2001; 938: 328-337.

  15. Storb R, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. In: Cthechter GP, Broudy VC, Williams ME.: Hematology 2001. The American Society of Hematology Education Program Book. Washington, USA 2002: 375-391.

  16. Childs R, Barrett. Graft-versus-tumor effects following non-myeloablative stem cell transplantation. In: Giralt S, Slavin S (editors). Non myeloablative stem cell transplantation. Darwin Scientific Publishing. Abingdon, Oxfordshire, UK. 2000: 113-126.

  17. Childs R, Clave E, Tisdale J, Plante M, Hensel N, Barret AJ. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2051.

  18. Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002; 76 (Suppl 1): 376-379.

  19. Georges GE, Storb R. Review of “minitransplantation”: Nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003; 77: 3-143.

  20. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martínez B, Abreu-Díaz G, Bravo G, Jaime-Pérez JC. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens. Leukemia Lymph 2001; 42: 145-150.

  21. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002; 7: 95-99.

  22. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004; 75: 200-204.

  23. Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single institution. Leukemia Lymph 2002; 43: 1509-1511.

  24. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-896.

  25. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, Cantú-Rodríguez OG, Herrera-Garza JL. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transpl 2003; 9: 157-161.

  26. Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, Hernández JM. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003; 8: 151-154.

  27. Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LC, Manzano C. Bloodless (transfusion-free) hematopoietic stem cell transplants: The Mexican experience. Bone Marrow Transpl 2005; 36: 715-720.

  28. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25: 131-133.

  29. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S; Latin American Cooperative Oncohematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043-7.

  30. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rangel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O, Herrera-Garza JL. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: A prospective study. Leukemia Lymphoma 2004; 45: 1191-1195.

  31. Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, González-Llano O, Salazar-Riojas R, Gonzalez-Martinez O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D. Non-myeloablative allogeneic hematopoietic stem cell transplantation in patients with acute myelogenous leukemia: The significance of the remission status. Biol Blood Marrow Transpl 2005; 11(Suppl 1): 61-62.

  32. Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, López-Martínez B. Trasplante de células hematopoyéticas alogénicas en niños y adolescentes empleando esquema de acondicionamiento no mieloablativo. Experiencia en una sola institución. Bol Med Hosp Inf Mex 2005; 62: 88-95.

  33. Spitzer TR. The expanding applications of non-myeloablative stem cell transplantation. Pediatr Transplant 2003; 7: 95-100.

  34. Gómez-Almaguer, González-Llano. Trasplante de células hematopoyéticas en niños. Bol Med Hosp Inf Mex 2005; 62: 85-87.

  35. 34a.Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Guitiérrez-Aguirre CH, Cantú-Rodríguez OG, Sobrevilla-Calvo P, Rivas-Vera S, Gómez-Rangel JD, Ruiz-Argüelles GJ. Allografting in patients with severe aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican Experience. Am J Hematol 2005, in press.

  36. Ruiz-Argüelles GJ, Gómez-Rangel D, Sánchez-Anzaldo J, Ruiz-Argüelles A, Porras-Ramírez G, Luis-López A. Trasplante de células de cordón umbilical: Informe de dos casos. Medicina Univ 2002; 4: 233-235.

  37. Ruiz-Argüelles GJ, Reyes-Núñez V, Garcés-Eisele J, Warwick RM, McKenna L, Ruiz-Reyes G, Granados J, Mercado-Díaz MA. Acquired hemoglobin S trait in an adult patient with secondary acute myelogenous leukemia allografted with matched unrelated umbilical cord blood cells using a non-ablative conditioning regimen. Haema 2005; 8: 492-496.

  38. Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin’s disease following autologous stem cell transplantation. Arch Med Res 2003; 34: 242-245.

  39. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241-244.

  40. Cantú-Rodríguez O, Gutiérrez H, Barrera D, González O, Mancías C, Jaime JC, Ruiz-Argüelles G, Gómez-Almaguer D. Outpatient stem cell transplantation: The Mexican experience with 132 patients. Haematologica 2005; 90(Suppl 2): 281.

  41. Ruiz-Argüelles GJ. Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica 2000; 85: 1233-1234.

  42. Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res 2003; 34: 554-557.

  43. Ruiz-Argüelles GJ. The Mexican approach to conduct allogeneic stem cell transplantation: Braking dogmata and facing the Matthew effect. Hematology 2005; 10(Suppl 1): 154-160.

  44. Gómez-Almaguer D. The simplification of the stem cell transplantation procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76(Suppl 1): 380-382.

  45. Ruiz-Argüelles GJ, Gómez-Almaguer D. Nephrotic syndrome after non-myeloablative stem cell transplantation. Brit J Haematol 2006; in press.

  46. Ruiz-Argüelles GJ, López-Martínez B, Manzano C, Gómez-Rangel JD, Lobato-Mendizábal E. Significance of one human leukocyte antigen mismatch on outcome of non-myeloablative allogeneic stem cell transplantation from related donors using the Mexican schedule. Bone Marrow Transpl 2005; 35: 335-339.

  47. Ruiz-Argüelles GJ, Gómez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, Gómez-Rangel JD, García-Ruiz-Esparza MA, López-Martínez B, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH. Extramedullary leukemic relapses following hematopoietic stem cell transplantation with non-myeloablative conditioning. Int J Hematol 2005; 82: 262-265.

  48. Ruiz-Argüelles GJ. Simplification, not demystification nor trivialization of stem cell transplantation. Haematologica 2001; 86: E07.

  49. Barr RD. The importance of lowering costs of stem cell transplantation in developing countries. Int J Hematol 2002; 76(Suppl 1): 365-367.

  50. Ruiz-Argüelles GJ, Ruiz-Reyes G. El tratamiento de las leucemias en países en desarrollo. En: Ruiz-Argüelles GJ, San-Miguel JF (editores). Actualización en Leucemias. Editorial Médica Panamericana. México City, México. 1996: 147-151.

  51. Ruiz-Argüelles GJ, Gómez-Almaguer D. Braking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-99.

  52. Chandy M. Management of hematological diseases in developing countries: Socio-economic aspects. In: Schechter GP, Hoffman R, Schrier SL (editors): Hematology 1999. The American Society of Hematology Education Program Book. Washington, USA 1999: 73-76.

  53. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewsky J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft versus-host-disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transpl 2004; 10: 178-185.

  54. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R. Morbidity and mortality with nonmyeloablative |compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1150-1158.

  55. Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de Leon A, Valcarcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Brit J Haematol 2005; 130: 394-403.

  56. Ruiz-Argüelles GJ. Introducción e historia del trasplante de médula ósea en México. Rev Hematol 2004; 5: 80-85.

  57. Gómez-Almaguer D, Ruiz-Argüelles GJ, Gutiérrez-Aguirre CH, Jaime-Pérez JC. Trasplante no mieloablativo de células progenitoras hematopoyéticas: Mitos y realidades. Rev Invest Clin Méx 2005; 57: 291-297.

  58. Kassim AA, Chinratanalab W, Ferrara JL, Minseishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leucemias: What is the best recipe?. Bone Marrow Transpl 2005; 36: 565-574.




2020     |     www.medigraphic.com